Bommagani Shobanbabu, Ponder Jessica, Penthala Narsimha R, Janganati Venumadhav, Jordan Craig T, Borrelli Michael J, Crooks Peter A
Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Division of Hematology, University of Colorado, Aurora, CO 80045, USA.
Eur J Med Chem. 2017 Aug 18;136:393-405. doi: 10.1016/j.ejmech.2017.05.031. Epub 2017 May 11.
A series of novel, heteroaryl carboxylic acid conjugates of the sesquiterpene melampomagnolide-B (MMB, 3) has been evaluated as antitumor agents against an NCI panel of 64 human hematopoetic and solid tumor cell lines. The indole-3-acrylic acid conjugate 7j and the indole-3-carboxylic acid conjugate 7k were found to be the most potent analogs in the series. Compounds 7j and 7k exhibited remarkable growth inhibition, with GI values in the range 0.03-0.30 μM and 0.04-0.28 μM, respectively, against the cell lines in the leukemia sub-panel, and GI values of 0.05-0.40 μM and 0.04-0.61 μM, respectively, against 90% of the solid tumor cell lines in the NCI panel. Compound 7a was particularly effective against the sub-panel of breast cancer cell lines with GI values in the range <0.01-0.30 μM. Compounds 7j, 7a and its water soluble analog 7p also exhibited potent anticancer activity against rat 9L-SF gliosarcoma cells in culture. Compound 7j was the most potent compound in the series in the M9-ENL1 AML cell assay with a lethal dose concentration EC value of 720 nM, and exhibited the greatest cytotoxicity against a collection of primary AML stem cell specimens, which included a specimen that was unresponsive to PTL, affording EC values in the range 0.33-1.0 μM in three out of four specimens. The results from this study provide further evidence that analogs of the sesquiterpene MMB can be designed to afford molecules with significantly improved anticancer activity. Thus, both 7j and 7k are considered potential lead molecules in the search for new anticancer agents that can be used as treatments for both hematopoetic and solid tumors.
已对一系列新型倍半萜美兰波马诺内酯 - B(MMB,3)的杂芳基羧酸共轭物作为抗肿瘤剂进行了评估,该评估针对美国国立癌症研究所(NCI)的64种人类造血和实体瘤细胞系组成的细胞株面板。发现吲哚 - 3 - 丙烯酸共轭物7j和吲哚 - 3 - 羧酸共轭物7k是该系列中最有效的类似物。化合物7j和7k表现出显著的生长抑制作用,针对白血病亚组中的细胞系,其GI值分别在0.03 - 0.30 μM和0.04 - 0.28 μM范围内,针对NCI面板中90%的实体瘤细胞系,其GI值分别为0.05 - 0.40 μM和0.04 - 0.61 μM。化合物7a对乳腺癌细胞系亚组特别有效,其GI值在<0.01 - 0.30 μM范围内。化合物7j、7a及其水溶性类似物7p在培养中对大鼠9L - SF胶质肉瘤细胞也表现出强大的抗癌活性。在M9 - ENL1急性髓细胞白血病(AML)细胞测定中,化合物7j是该系列中最有效的化合物,致死剂量浓度EC值为720 nM,并且对一组原发性AML干细胞标本表现出最大的细胞毒性,其中包括一个对PTL无反应的标本,在四个标本中的三个中,其EC值在0.33 - 1.0 μM范围内。这项研究的结果提供了进一步的证据,表明倍半萜MMB的类似物可以被设计成具有显著改善的抗癌活性的分子。因此,7j和7k都被认为是寻找可用于治疗造血和实体瘤的新型抗癌剂的潜在先导分子。